• Prasad Kulkarni on dengue monoclonal antibodies

  • Feb 23 2024
  • Length: 19 mins
  • Podcast

Prasad Kulkarni on dengue monoclonal antibodies

Listen for free

View show details

  • Summary

  • Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

    Read the full article:
    https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show More Show Less
activate_samplebutton_t1

What listeners say about Prasad Kulkarni on dengue monoclonal antibodies

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.